Doptelet FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 7, 2020.
FDA Approved: Yes (First approved May 21, 2018)
Brand name: Doptelet
Generic name: avatrombopag
Dosage form: Tablets
Company: Dova Pharmaceuticals, Inc.
Treatment for: Thrombocytopenia, Immune Thrombocytopenia
Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of:
- Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Development timeline for Doptelet
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
